Toripalimab Gets Priority Review for Nasopharyngeal Carcinoma
The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License Application for toripalimab, in combination with gemcitabine and cisplatin, for the first-line treatment of patients with advanced recurrent or metastatic nasopharyngeal…